Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...
Zacks Investment Research on MSN
How strong is AbbVie's immunology franchise after Humira's LOE?
AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — ...
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback